Zacks.com on MSN57m
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary GoalSYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback